Bolivia Orders Pre-Trial Detention of Former President Luis Arce Over Embezzlement Probe 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
New Zealand Budget Outlook Shows Prolonged Deficits Despite Economic Recovery Hopes 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Italy Supreme Court Upholds Salvini Acquittal in Migrant Kidnapping Case 
Federal Appeals Court Allows Trump’s National Guard Deployment in Washington, D.C. to Continue 
U.S. Dollar Slips Near Two-Month Low as Markets Await Key Jobs Data and Central Bank Decisions 
Chinese Robotaxi Stocks Rally as Tesla Boosts Autonomous Driving Optimism 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Australian Consumer Sentiment Slumps in Early December as Inflation Fears Resurface 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee 
Brazil Arrests Former Peruvian Foreign Minister Augusto Blacker Miller in International Fraud Case 
Fifty-seven lawsuits alleging that hair relaxer products sold by L'Oreal USA Inc and two India-based firms cause cancer and other health problems will be consolidated before US District Judge Mary Rowland in Chicago,
The Chicago federal court will streamline discovery efforts and other pretrial issues for the cases, according to the order.
The lawsuits, which have been filed in federal courts across the country, alleged that the companies knew about the dangerous chemicals in their products but marketed and sold them anyway.
The cases name the US subsidiary of L'Oreal SA and subsidiaries of India-based companies Godrej SON Holdings Inc. and Dabur International Ltd.
Representatives for the companies opposed the centralization of the cases.
L'Oreal said it is confident in the safety of its products and that lawsuits against it have no legal merit.
The claims come in response to a National Institutes of Health research that was published in October and revealed that women who used the products frequently had a greater than doubled risk of developing uterine cancer.
The panel's decision, according to Diandra Debrosse Zimmermann of DiCello Levitt, who filed the initial case after the study's publication, "recognized the clear benefits of centralizing the hair relaxer litigation," and she anticipates that many more companies will do the same in the upcoming weeks.
As the goods are often promoted to women of color, Zimmermann expects hundreds of women may end up suing over them.
